Lead Sponsor

UNC Lineberger Comprehensive Cancer Center

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•≥ 18 years of age;
•Histologically confirmed Stage I-IV breast cancer;
•ECOG Performance Status 0-3;
•Scheduled to start a new course of chemotherapy in the neo-adjuvant, adjuvant or metastatic setting for newly diagnosed or recurrent disease;
•Growth factors, e.g., filgrastim, pegfilgrastim, are allowed, but their dose and duration will be tracked.
•Absolute Lymphocyte Count (ALC) \> 500 cells/μL as determined by routine CBC with differential;
•Signed, IRB approved written informed consent.

•Presence of acute, active infection;
•History of clonal bone marrow disorder (i.e., myelodysplastic or myeloproliferative disorder, acute or chronic leukemia);
•Other co-morbid illness which would impair ability to participate in the study;
•Concurrent experimental therapy (Note: concurrent biologic therapy IS permitted, provided it is not experimental).
•Prior or current receipt of histone deacetylase (HDAC) inhibitors

Related studies

NCT07586215 · Breast Cancer Metastatic

NCT05831878 · Advanced Breast Cancer

NCT07368998 · Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

NCT07578064 · Breast Cancer, Bone Marrow Suppression

Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients